REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…
REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in…
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest…
TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that…
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage…
ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on…
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection…
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP)…
How Decades of Innovation Are Converging for Commercial Spider Silk SuccessDENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer…
How Decades of Innovation Are Converging for Commercial Spider Silk SuccessDENVER, Dec. 10, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer…